Ardelyx Inc. is ranked 9th on hedge funds' list of best biotech penny stocks to buy
From Yahoo Finance: 2025-04-16 11:21:00
- FDA’s Peter Marks’ departure raises concerns about review program and future FDA stability, causing investors to look for biotech names less reliant on FDA approvals.
- Stifel’s Paul Matteis advises investors to focus on companies with de-risked profiles amid FDA uncertainty, highlighting short-term delays in drug approvals and the need for more selective stock selections.
- Matteis notes that companies tied to commercial launches are outperforming, signaling a shift in focus away from FDA-dependent firms in the biotech sector.
- Ardelyx Inc. (NASDAQ:ARDX) is ranked 9th on the list of best biotech penny stocks to buy according to hedge funds, with a focus on XPHOZAH’s growth potential and AI stocks as promising investments in a shorter timeframe.
- Ardelyx Inc. (NASDAQ:ARDX) commercializes medicines like IBSRELA and XPHOZAH, generating $57.2 million in net product sales revenue in Q4 2024, with projections for $750 million in annual net sales revenue before XPHOZAH’s patent expires.
- Medicare Part D coverage for XPHOZAH was eliminated in January, but Ardelyx is dedicated to ensuring patient access through education and support programs like ArdelyxAssist.
Read more: Is Ardelyx Inc. (NASDAQ:ARDX) the Best Biotech Penny Stock to Buy According to Hedge Funds?